Jail time and fines in any other industry would be imposed if the price fixing laws were followed--but as more companies like Theranos and the Oklahoma surgical Center post prices the lawless healthcare industry will implode and prices plummet Pricing at Theranos is 1/10 th the prices of Lab Corp
BS pumper you belong in the dumpster You must be one of the promoters and live in Israel Calling me names will not shut me up ---facts are facts
I have been in the pharma business for years and know you can't do phase studies for thousands it take millions of dollars so all this phase 1,2 ,3 is very very suspect and I am not new to real drug studies but have seen these pump and dump out of Israel often
this stock trades like a manipulated shell---very little money --how in the world have they done all these studies as they cost millions for a valid drug company to run and this stock has nothing
The Street is a robot rating system that is ignorant of pipe line drugs etc. only looks at financials from the past not predictive of future earning from new sales of developing drugs and markets
You have to pay your dues---go to their web site and read and listen to their web casts--829 phase 2 study results by Oct perhaps results are leaking out now
In Receptos June '15 investor presentation it compares ozanimod as equivalent to Tecfidera in treating MS ---thus 829 as an improved Tecfidera should value XNPT much higher even in the three digit range when 829 study is known-- I rate the study success at 90% favorable along with the hedge fund Baker Brothers but time will tell
Don't know but Horizant sales must be improving Anyone know the most resent sales data ?
17 million suffer with AUD (alcohol use disorder) Horizant dulls the craving for alcohol allowing the suffer to abstain from drinking more easily.
The government has already run a study using gabapentin and had a 17% favorable result over a placebo.
the government thinks compliance by the subjects will be better using time release gabapentin (Horizant) and thus the study results will be improved beyond 17%. This may be another gold mine for xnpt over the coming years when results are known and another huge market for Horizant
Nice I would sell too if it were based on present cash fundamentals ---but this recommendation doesn't look to the future earnings for pipe line drugs (like 829) Perhaps this will create a buying opportunity
I think it is a computer program--If you look at the price chart every time the price moves to just under a previous high --a large volume spike seems to occur and the price rolls over--I am encourage that the price didn't drop much ---so another computer program must be buying now also---but who knows only the big banks HFT and other market manipulators know the answer --certainly not the lap dog regulators the were bought off years ago
BIIB's patent for dosage of Tecfidera is under assault by Kyle Bass and by Forward Pharma. To protect the $3+billion market in MS when XNPT's 829 is successful in phase 2 and its long patent life a buy out will become even more likely by BIIB or some other drug Co in MS space
Kyle Bass has a lawsuit vs BIIB and other bio co that use dosage as a basis for a patent--another reason xnpt 829 may be of great value in the future
Requip a dopa drug sells over $ 400 million for RLS and Parkinsons annually Horizant was called to sell $39 to $43 million this year But now with expert committee calling Horizant first line drug with no augmentation risk
I can hear a patient saying Doctor you gave me Requip and you knew about the augmentation risk please send me and my lawyer $500000 for damages--- You should have used Horizant
this will convince physicians to use Horizant or get sued by a patient who develops augmentation due to dopa based drugs later on